About this Research Topic
The incidence of allergic diseases has dramatically increased in the last decades. The dysregulation of our immune systems seems to follow a skin-gastrointestinal-respiratory tract evolution. We are observing multimorbidity in the atopic conditions as well as a series of sequential events in the natural process of allergic disease that we define as ‘atopic march.’ Very often the dysregulation starts as atopic dermatitis that later progresses to food allergy or asthma among other diseases. There seems to be a common starting mechanism for all these conditions.
We have achieved broad knowledge in all the separate manifestations of atopy. However, we need to have a better understanding of the critical steps in the onset and the mechanisms of the atopic march and put the puzzle together to investigate the original triggers and the subsequent cascade of events. This knowledge is urgently required to develop strategies for the prevention and treatment of atopic diseases.
Suitable themes for manuscripts include but are not limited to:
● What is (are) the triggering factor(s) that ignite the atopic march?
● Role of Epidermal Barrier Dysfunction, Transcutaneous Sensitization, Filaggrin, and Microbiome Alteration in the initiation of atopic dermatitis.
● Causes of epidermal barrier dysfunction: possible role of textile dyes in barrier damage.
● What is the relationship and common denominator(s) in the different diseases of the atopic march?
● Investigate further the sequence of events leading to this relationship.
● Are mast cells the link between all diseases of the atopic march?
● Investigate genetic associations and polymorphisms leading to higher susceptibility to atopic march.
● Is the final stage of the atopic march autoimmunity? BACH2 gene and other markers.
● Animal models for the study of atopic march.
All article types accepted by Frontiers are welcome.
Conflict of Interest Declaration-
Topic Editor Evan Dellon has declared the following conflict of interest:
Research funding: Adare/Ellodi, Allakos, Arena/Pfizer, AstraZeneca, GSK, Meritage, Miraca, Nutricia, Celgene/Receptos/BMS, Regeneron, Revolo, Shire/Takeda
Consultant: Abbott, Abbvie, Adare/Ellodi, Aimmune, Akesobio, Alfasigma, ALK, Allakos, Amgen, Aqilion, Arena/Pfizer, Aslan, AstraZeneca, Avir, Biorasi, Calypso, Celgene/Receptos/BMS, Celldex, Eli Lilly, EsoCap, Eupraxia, Ferring, GSK, Gossamer Bio, Holoclara, Invea, Knightpoint, Landos, LucidDx, Morphic, Nexstone Immunology, Nutricia, Parexel/Calyx, Phathom, Regeneron, Revolo, Robarts/Alimentiv, Salix, Sanofi, Shire/Takeda, Target RWE, Upstream Bio.
We have achieved broad knowledge in all the separate manifestations of atopy. However, we need to have a better understanding of the critical steps in the onset and the mechanisms of the atopic march and put the puzzle together to investigate the original triggers and the subsequent cascade of events. This knowledge is urgently required to develop strategies for the prevention and treatment of atopic diseases.
Suitable themes for manuscripts include but are not limited to:
● What is (are) the triggering factor(s) that ignite the atopic march?
● Role of Epidermal Barrier Dysfunction, Transcutaneous Sensitization, Filaggrin, and Microbiome Alteration in the initiation of atopic dermatitis.
● Causes of epidermal barrier dysfunction: possible role of textile dyes in barrier damage.
● What is the relationship and common denominator(s) in the different diseases of the atopic march?
● Investigate further the sequence of events leading to this relationship.
● Are mast cells the link between all diseases of the atopic march?
● Investigate genetic associations and polymorphisms leading to higher susceptibility to atopic march.
● Is the final stage of the atopic march autoimmunity? BACH2 gene and other markers.
● Animal models for the study of atopic march.
All article types accepted by Frontiers are welcome.
Conflict of Interest Declaration-
Topic Editor Evan Dellon has declared the following conflict of interest:
Research funding: Adare/Ellodi, Allakos, Arena/Pfizer, AstraZeneca, GSK, Meritage, Miraca, Nutricia, Celgene/Receptos/BMS, Regeneron, Revolo, Shire/Takeda
Consultant: Abbott, Abbvie, Adare/Ellodi, Aimmune, Akesobio, Alfasigma, ALK, Allakos, Amgen, Aqilion, Arena/Pfizer, Aslan, AstraZeneca, Avir, Biorasi, Calypso, Celgene/Receptos/BMS, Celldex, Eli Lilly, EsoCap, Eupraxia, Ferring, GSK, Gossamer Bio, Holoclara, Invea, Knightpoint, Landos, LucidDx, Morphic, Nexstone Immunology, Nutricia, Parexel/Calyx, Phathom, Regeneron, Revolo, Robarts/Alimentiv, Salix, Sanofi, Shire/Takeda, Target RWE, Upstream Bio.
Keywords: atopic dermatitis, food allergy, eosinophilic esophagitis, immunity
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
